LivaNova (LIVN) Stock Price, News & Analysis

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings or view top-rated stocks.

5 brokers have issued twelve-month price targets for LivaNova's stock. Their LIVN share price targets range from $52.00 to $75.00. On average, they predict the company's stock price to reach $64.40 in the next year. This suggests a possible upside of 23.1% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.

LivaNova's stock was trading at $51.74 on January 1st, 2024. Since then, LIVN shares have increased by 1.1% and is now trading at $52.33.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LIVN earnings forecast.

LivaNova will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

LivaNova PLC (NASDAQ:LIVN) announced its earnings results on Wednesday, February, 21st. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a trailing twelve-month return on equity of 12.23% and a net margin of 1.53%. LivaNova's revenue was up 12.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.81 EPS.

ETFs with the largest weight of LivaNova (NASDAQ:LIVN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), IQ Healthy Hearts ETF (HART), Simplify Health Care ETF (PINK) and Invesco S&P MidCap 400 GARP ETF (EWMC).iShares U.S. Medical Devices ETF (IHI).

LivaNova issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of $2.95-3.05 for the period, compared to the consensus estimate of $2.99.

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

LivaNova's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.46%), Perpetual Ltd (0.41%), State of Michigan Retirement System (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends.

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.